Aarti Drugs Limited · NSE:AARTIDRUGS
Aarti Drugs — Shareholder Meeting (September 2024)
22 slides from Aarti Drugs's shareholder meeting presentation, Sep 20, 2024
Slide 1: Presentation to Shareholders cover letter to exchanges
Ref: ADL/SE/2024-25/74 September 20, 2024 To, To, Listing/ Compliance Department Listing/ Compliance Department BSE Limited National Stock Exchange of India Limited, Phiroze Jeejeebhoy Towers, “Exchange Plaza”, Plot No. C/1, Dalal Street, G Block Bandra - Kurla Complex, Mumbai – 400 001 Bandra (East
Slide 2: Annual General Meeting September 20, 2024
AARTI DRUGS LIMITED Annual General Meeting September 20, 2024
Slide 3: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Aarti Drugs Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securiti
Slide 4: Company Overview
3 Company Overview
Slide 5: Key Milestones
Key Milestones 2024 Consolidated Revenue Rs. 2,500+ Cr 2017 Pinnacle Life Science Pvt. Ltd. crossed Rs. 100 crores turnover 2021 Crossed Rs. 2,000 Cr 2003 Consolidated Turnover & Rs. 1996 Listed on National Stock Exchange 200 Cr Formulations Turnover Amalgamation of Rupal Chemical of India Limited I
Slide 6: Key Facts & Figures
Key Facts & Figures Largest producer of Nimesulide in the world. 13 4,765 Manufacturing MT/Monthly Facilities Capacity Largest producer of Metronidazole in Largest producer of India Ketoconazole in the world 80+ 1,26,642 Finished Products Sq.m Plant Area Leadership in API One of the leading Manufact
Slide 7: Diversified presence across segments
Diversified presence across segments Presence Across API, Formulation, Specialty Chemicals, Intermediates Segments Active Pharmaceuticals Ingredients Formulation Specialty Chemicals, (API) Intermediates & Others Leading API producer of 50+ molecules for anti- Diversified into formulation through
Slide 8: State-of-the-art Integrated manufacturing facilities
State-of-the-art Integrated manufacturing facilities Baddi Pinnacle Plant Formulation Plant WHO-GMP Sarigam-1 WHO-GMP Sarigam-2 WHO-GMP/ COFEPRIS/CEP E-22 W-61 Australian Government – Department of Health and EUGMP & WHO-GMP Ageing - Therapeutic Goods Administration EUGMP / WHO-GMP / Japanese Ac
Slide 9: Strong R&D thrust on continuous innovation
Strong R&D thrust on continuous innovation R&D Center at Tarapur R&D Center at Turbhe, Mumbai 2 Supports manufacturing facilities at Tarapur and Sarigam on API process development Supports development of complex generics for in-house formulation business Pilot plant used for kilo scale manufac
Slide 10: Diversified geographic presence
Diversified geographic presence Presence in 100+ Countries across Top 10 Countries - Exports 6 Continents ensures Pakistan Turkey diversification and risk minimization Brazil Mexico Europe Switzerland UAE 15% 14% Indonesia Egypt FY23 FY24 Asia Bangladesh Nigeria North America Market Share 51% 57% FY
Slide 11: ESG Initiatives
ESG Initiatives Environmental Social Governance • Converted multiple facilities into to Zero Liquid • Woman Empowerment: Free Government • The Board has an optimum combination of Discharge (ZLD) approved and certified vocational course training Executive and Non-Executive directors and for women to
Slide 12: Corporate Social Responsibility
Corporate Social Responsibility Donation of Inverter, Water filters, Air coolers Steel cupboards, Ambulance donated Salwad, Gram Panchayat, Dist. Palghar, MH, Sunroof, supply of Tree Plantation Programs medicines 11
Slide 13: Capex to drive the next leg of growth
Capex to drive the next leg of growth Capex of Rs. 600 crores underway [starting from FY22 for the next 4-5 years] Capex plans Phase wise capex will lead to distributed investments Majority of the capex to be funded through internal accruals and minimal debt Brownfield expansion and debottlenecking
Slide 14: Financial Highlights
13 Financial Highlights
Slide 15: FY24 Result Highlights
FY24 Result Highlights Rs. crores Net Revenue from Operations EBITDA & EBITDA Margin (%) PAT & PAT Margin (%) 11.3% 12.7% 6.1% 6.8% +4.1% +3.1% 2,718 308 320 166 172 2,533 FY23 FY24 FY23 FY24 FY23 FY24 1. EBITDA includes other income & excludes exceptional items 14
Slide 16: FY24 Segmental Break-up
FY24 Segmental Break-up FY23 FY24 10% 13% 82% 5% 5% 80% 3% 2% API Formulation API Formulation Speciality Chemicals Intermediates & Others Speciality Chemicals Intermediates & Others 15
Slide 17: Q1 FY25 Result Highlights
Q1 FY25 Result Highlights Rs. crores Net Revenue from Operations EBITDA & EBITDA Margin (%) PAT & PAT Margin (%) 12.8% 11.9% 7.3% 6.0% -16% -22% -31% 661 85 48 555 66 33 Q1 FY24 Q1 FY25 Q1 FY24 Q1 FY25 Q1 FY24 Q1 FY25 Q1 FY25 Q1 FY24 Segmental Breakup 12% 14% 80% 5% 79% 4% 3% 3% API Formulation API
Slide 18: Historical Performance At A Glance
17 Historical Performance At A Glance
Slide 19: Strong Financial Performance
Strong Financial Performance Consolidated Revenue (Rs. Crores) EBITDA (Rs. Crores) PAT (Rs. Crores) 2,718 442 280 2,500 2,533 2,159 341 308 321 205 1,808 263 166 172 141 FY20 FY21 FY22 FY23 FY24 FY20 FY21 FY22 FY23 FY24 FY20 FY21 FY22 FY23 FY24 EBITDA Margin (%) PAT Margin (%) 20.5% 13.0% 14.6% 13.7
Slide 20: Strong Financial Performance
Strong Financial Performance Consolidated EPS* (in Rs.) Net Worth (in Rs. Crores) Leverage (X) 30.1 1,282 0.6 1,193 0.5 0.5 1,036 22.1 0.4 913 18.0 18.6 0.4 15.4 653 FY20 FY21 FY22 FY23 FY24 FY20 FY21 FY22 FY23 FY24 FY20 FY21 FY22 FY23 FY24 * For EPS, adjusted includes previous year’s figures in pro
Slide 21: Distribution to Shareholders
Distribution to Shareholders (in Rs. Crs) Distribution Policy Distributed ~Rs. 65.2 Crores as Dividend over last 7 years Distribution: ~23.0% Considering various financial parameters, the Company Distributed ~ Rs. 262 crores in may elect to distribute about form of dividend & buyback of 15% to 30% o
Slide 22: For further information, please contact
For further information, please contact Company: Investor Relations Advisor: CIN: L37060MH1984PLC055433 CIN: U74140MH2010PTC204285 Mr. Rushikesh Deole Mr. Deven Dhruva Email: investorrelations@aartidrugs.com E: deven.dhruva@sgapl.net Contact no.: +91 22 24048199 T: +91 98333 73300 www.aartidrugs.co.